Granules India has reported results for first quarter ended June 30, 2019.
The company has reported a rise of 50.44% in its net profit at Rs 59.53 crore for the quarter under review as compared to Rs 39.57 crore for the same quarter in the previous year. Total income of the company increased by 24.22% at Rs 569.36 crore for Q1FY20 as compared Rs 458.36 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 60.69% in its net profit at Rs 83.24 crore for the quarter under review as compared to Rs 51.80 crore for the same quarter in the previous year. Total income of the company increased by 27.60% at Rs 597.13 crore for Q1FY20 as compared Rs 467.98 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: